NCT05113927 (RCT) is a NA clinical trial of Selene in Breast Cancer, sponsored by Perimeter Medical Imaging.

Who is sponsoring NCT05113927?

NCT05113927 is sponsored by Perimeter Medical Imaging.

What drugs are being tested in NCT05113927?

Interventions in NCT05113927: Selene.

What condition does NCT05113927 study?

NCT05113927 studies Breast Cancer.

Is NCT05113927 still recruiting?

NCT05113927 is currently completed. Last updated 2 December 2024.

Last reviewed 2024-12-02 · How we verify

NCT05113927: RCT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

Completed NA Last updated 2 December 2024

What this trial tests

NA trial testing Selene in Breast Cancer in 482 participants. Completed in 21 October 2024.

Timeline

1 December 2021

Primary endpoint
23 September 2024

21 October 2024

Quick facts

Lead sponsor	Perimeter Medical Imaging
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	482
Start date	1 December 2021
Primary completion	23 September 2024
Estimated completion	21 October 2024
Sites	10 locations across United States

Drugs / interventions tested

Selene

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Perimeter Medical Imaging

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, randomized, two-arm study designed to measure the effectiveness of the SELENE system in reducing the number of unaddressed positive margins in breast lumpectomy procedures when used in addition to standard intraoperative margin assessment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Perimeter Medical Imaging trials

Trials by the same sponsor.

NCT04242277 — Wide-field Optical Coherence Tomography Imaging of Excised Breast Tissue. · completed
NCT04314700 — Intraoperative Use of an Optical Coherence Tomography (OCT) Imaging System to Guide Additional Margin Cavity Shaves in B · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05113927 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Perimeter Medical Imaging
Last refreshed: 2 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05113927.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing